600079.SH
ST人福
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 17.85
−0.22%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
33.4x
EV/EBITDA
9.0x
Market Cap
CNY 29.14B
MomentumView details →
1D Return
−0.22%
YTD Return
+3.42%
RSI (14)
65.0
ValuationView details →
P/E (Fwd)
33.4x
EV/EBITDA
9.0x
Market Cap
CNY 29.14B
RSI (14)
65.0
MomentumView details →
1D Return
−0.22%
YTD Return
+3.42%
Similar companies
Latest newsMore news →
ST Renfu's controlled subsidiary Yichang Renfu announced that its drug RFUS-949 tablets have entered Phase II clinical trials for the treatment of acute and chronic pain.1d agoHumanwell Healthcare's subsidiary Yichang Humanwell Pharmaceutical received acceptance of its marketing authorization application for pregabalin extended-release tablets from China's National Medical Products Administration.5d agoST Renfu's wholly-owned subsidiary Wuhan Puke obtained a drug registration certificate for Vinorelbine Tartrate Soft Capsules, valid until July 20, 2031.43d ago